These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 8962321)

  • 21. Therapy of aluminum overload (I).
    Pierides AM; Myli MP
    Contrib Nephrol; 1984; 38():65-77. PubMed ID: 6425013
    [No Abstract]   [Full Text] [Related]  

  • 22. [Effect of deferoxamine on erythropoiesis in patients hemodialyzed for chronic renal insufficiency treated with erythropoietin].
    Kalinowski M; Popławski A; Kaliszewski Z; Juzwiuk J
    Pol Merkur Lekarski; 1996 Oct; 1(4):232-4. PubMed ID: 9156931
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Encephalopathy in chronic renal failure responsive to deferoxamine therapy. Another manifestation of aluminum neurotoxicity.
    Sprague SM; Corwin HL; Wilson RS; Mayor GH; Tanner CM
    Arch Intern Med; 1986 Oct; 146(10):2063-4. PubMed ID: 3767553
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapy of aluminium overload (II).
    Ackrill P; Day JP
    Contrib Nephrol; 1984; 38():78-80. PubMed ID: 6713902
    [No Abstract]   [Full Text] [Related]  

  • 25. Aluminum intoxication of bone in renal failure--fact or fiction?
    Malluche HH; Faugere MC; Smith AJ; Friedler RM
    Kidney Int Suppl; 1986 Feb; 18():S70-3. PubMed ID: 3458000
    [No Abstract]   [Full Text] [Related]  

  • 26. Estimation of aluminoxamine and ferrioxamine in plasma by high performance liquid chromatography.
    Hughes H; Hagen LE; Cameron EC; Sutton RA
    Clin Chim Acta; 1986 May; 157(1):115-20. PubMed ID: 3719992
    [No Abstract]   [Full Text] [Related]  

  • 27. Continuous ambulatory EEG monitoring following desferrioxamine (DFO) i.v. infusion.
    Poignet JL; Monge MF; Ciancioni C; Mikol F; Naret C; Delons S; Man NK
    Trans Am Soc Artif Intern Organs; 1985; 31():546-51. PubMed ID: 3837504
    [No Abstract]   [Full Text] [Related]  

  • 28. Fracture healing with deferoxamine therapy in a patient with aluminum-associated osteomalacia.
    Phelps KR; Einhorn TA; Vigorita VJ; Lundin AP; Friedman EA
    ASAIO Trans; 1986; 32(1):198-200. PubMed ID: 3778712
    [No Abstract]   [Full Text] [Related]  

  • 29. [Treatment of aluminum-induced osteopathy with desferrioxamine in dialysis-dependent renal failure].
    Lechleitner P; Gmeiner R; Beck G; König P
    Wien Med Wochenschr; 1987 Aug; 137(14-15):355-60. PubMed ID: 3673100
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prophylaxis and methods for early recognition of aluminium intoxication.
    Fuchs C; Armstrong VW; Quellhorst E; Scheler F
    Contrib Nephrol; 1984; 38():81-94. PubMed ID: 6713903
    [No Abstract]   [Full Text] [Related]  

  • 31. [Speech apraxia in dialysis-associated aluminum encephalopathy].
    Haug BA; Botsch G; Felgenhauer K
    Nervenarzt; 1991 Oct; 62(10):637-40. PubMed ID: 1749454
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of trace elements in peritoneal dialysis, hemodialysis, and uremia.
    Thomson NM; Stevens BJ; Humphery TJ; Atkins RC
    Kidney Int; 1983 Jan; 23(1):9-14. PubMed ID: 6834697
    [No Abstract]   [Full Text] [Related]  

  • 33. Microcytic anemia in dialysis patients: reversible marker of aluminum toxicity.
    Swartz R; Dombrouski J; Burnatowska-Hledin M; Mayor G
    Am J Kidney Dis; 1987 Mar; 9(3):217-23. PubMed ID: 3826071
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Concentration of selected trace elements in the blood of patients with chronic renal failure].
    Adamiec R; Weyde W
    Pol Tyg Lek; 1982 Dec; 37(48):1421-4. PubMed ID: 7183997
    [No Abstract]   [Full Text] [Related]  

  • 35. [Changes in the levels of various trace elements in the blood of patients with chronic renal failure treated by repeat hemodialysis and in disorders of peripheral motor conductivity].
    Weyde W; Adamiec R; Rudkowska A
    Przegl Lek; 1987; 44(4):397-9. PubMed ID: 2819955
    [No Abstract]   [Full Text] [Related]  

  • 36. Treatment and histological healing of aluminum-related osteomalacia.
    Boyce BF; Mocan MZ; Byars J; Junor BJ
    Contrib Nephrol; 1988; 64():151-9. PubMed ID: 3180822
    [No Abstract]   [Full Text] [Related]  

  • 37. Deferoxamine and aluminum removal.
    Swartz RD
    Am J Kidney Dis; 1985 Nov; 6(5):358-64. PubMed ID: 3904429
    [No Abstract]   [Full Text] [Related]  

  • 38. Trace elements and complications in patients undergoing chronic hemodialysis.
    Hosokawa S; Oyamaguchi A; Yoshida O
    Nephron; 1990; 55(4):375-9. PubMed ID: 2392189
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Indications for desferrioxamine in patients with chronic renal insufficiency treated by dialysis].
    Simon P
    Nephrologie; 1986; 7(5):177-80. PubMed ID: 3822038
    [No Abstract]   [Full Text] [Related]  

  • 40. Red blood cell aluminum in patients with renal failure and effect of desferrioxamine infusion.
    Umeda M; Tsurusaki K; Kamikawa S; Izumi N; Yasumoto R; Kishimoto T; Maekawa M
    Blood Purif; 1990; 8(5):295-300. PubMed ID: 2091689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.